UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Jade Biosciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 2836 83-137788 (Primary Standard Industrial Classification Code Number) 221 Crescent St., Building 23 Suite 105 Waltham, MA 02453 (781) 312-3013 (Address, including zip code, and telephone number, including area code, of regist ...

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 8, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Akston Biosciences Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 45-4562397 (I.R.S. Employer Identification ...

Table of Contents As filed with the Securities and Exchange Commission on September 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOLIGENIX, INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (609) 538-8200 (Name, Address, Including Zip Code, and Telephone Num ...

Core Viewpoint - Neurocrine Biosciences (NBIX) is a biopharmaceutical company focused on developing treatments for neurology and neuroendocrinology, with a strong commercial portfolio and an expanding pipeline [1] Group 1: Commercial Portfolio - The two most important commercial drugs for Neurocrine Biosciences are Ingrezza and another unnamed product [1]

Core Insights - GSK plc is a prominent biopharmaceutical company focused on developing specialty and general drugs, as well as vaccines [1] Financial Performance - GSK's Q1 2025 results demonstrated strong momentum, particularly in the specialty medicines segment [1] - The oncology performance of GSK was noted as excellent, indicating a robust growth area for the company [1]

As filed with the Securities and Exchange Commission on March 24, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-4369909 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 2223 Avenida de la Playa, # ...

As filed with the U.S. Securities and Exchange Commission on October 15, 2024. Registration No. 333-279771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 7 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specified in its charter) ______________________________ Ontario, Canada 2834 98-1778211 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Cl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on December 21, 2023. Registration No. 333- GRI BIO, INC. (Exact name of registrant as specified in its charter) (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Adam Lenain, Esq. Melanie Ruthrauff Levy, Esq. Jason Miller, Esq. Mintz, Levin, Cohn, Ferris, Glo ...